The team chapter — who's on the journey, and how each role is respected through to viability and raise.
ORCAA - Cardiac · Clinical · Care · Connect · Clinical Management.
Each product targets a distinct clinical or care context, sharing the same ingestion, scoring, and escalation stack underneath.
Continuous post-op monitoring — hospital & remote.
Pre-pilot — clinical validation imminent
Acute post-surgical wards and post-discharge home monitoring. Same scoring stack, two deployment contexts.
Continuous ECG analysis and escalation.
Pre-pilot — production UI live, pending AU data warehousing
Cardiac wards, post-cardiac-surgery, cardiac rehab, ambulatory monitoring.
Directory of health providers.
In development / prototype
Identity / directory layer across the portfolio — who is the clinician, where to refer, how to escalate.
Disability and aged-care management.
In development / prototype — productisation pending
Individuals self-managing health + care providers in disability / aged-care sectors. NDIS-adjacent.
Empowering personal health.
Early-stage
General consumer / individual health app. Deliberately separated from Care to keep that product's disability / aged-care positioning clean.
Clinical, Cardiac, Connect, Care, and Personal all sit on the same audited substrate. This is the moat.
Colorectal pilot for Clinical; AU migration + escalation tuning for Cardiac; TGA / ISO 13485 readiness; first reference customers.
Paying customers OR signed letters of intent / pre-orders pending TGA/ISO; distribution agreements (incl. ECG247 conversion).
Multi-million raise; expand build team; founder no longer single point of failure; 50% floor preserved through this round.
Founder
Co-Founder
Founding clinical partner
Distribution & strategic build
Industry advisor — market & impact
Surgical Rep / Strategic Alliances
Hardware advisory — design, testing, manufacturing, compliance
Cybersecurity / Compliance Advisor
Raise sized to extend runway through validated commercial traction, not to chase top-line vanity.
Production / engineering capacity must expand so the company is not reliant on my sweat as the technical bottleneck.
Founder shareholding held at or above 50% through this round. Limited dilution across all existing stakeholders.
The raise lands on a sharpened, defensible market story and a roadmap that survives diligence.
Founder stake may drop below 50% on an exit or once a strong management team runs ORCAA — not in this round.
Baseline Mick 20% / Nick 15% of Clinical+Cardiac participation; flexibility to Mick 25 / Nick 15–20 (or both at 20%) if the delivered value warrants. Nick stays at or below Mick.
Cardiac UI live in production; Clinical pre-pilot with ALRS scoring stack; shared L1–L5 platform
Colorectal pilot (Clinical); AU migration & escalation tuning (Cardiac); TGA / ISO 13485 readiness; ECG247 and first reference customers
Stakeholders confirm scope; commercial milestones locked; raise readiness Q4
Anchor decisions against this. Iterate on what's still open.